Antara Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-3,000,000
Closed -$5.4M 302
2022
Q2
$5.4M Buy
+3,000,000
New +$4.43M 0.23% 81
2021
Q4
Sell
-510,000
Closed -$2.27M 282
2021
Q3
$2.27M Sell
510,000
-1,490,000
-75% -$7.18M 0.17% 86
2021
Q2
$11.6M Buy
+2,000,000
New +$11.7M 0.63% 35
2021
Q1
Sell
-42,500
Closed -$204K 135
2020
Q4
$204K Buy
+42,500
New +$215K 0.04% 33
2020
Q1
Sell
-2,638,200
Closed -$27.5M 59
2019
Q4
$27.5M Buy
2,638,200
+1,388,200
+111% +$10.1M 5.57% 4
2019
Q3
$4.91M Buy
1,250,000
+1,241,600
+14,781% +$10M 2.28% 11
2019
Q2
$124K Buy
+8,400
New +$152K 0.03% 53

Other funds holding CLVS

Antara Capital's CLVS Position: Q3 2019 in Review

Antara Capital sold out of Clovis Oncology, Inc. (CLVS) in Q3 2019, closing a stake of 50,000 shares — an estimated $404K sold.

Antara Capital first reported a position in CLVS in Q4 2018 and held it in 3 quarters. The position peaked at $2.15M in Q4 2018. 153 funds tracked by Wall St. Rank hold CLVS as of Q3 2019.

  • Antara Capital reported no remaining Clovis Oncology, Inc. position as of Q3 2019 after selling out during the quarter.
  • Antara Capital sold 50,000 Clovis Oncology, Inc. shares in Q3 2019, an estimated $404K.
  • Antara Capital first reported a position in Clovis Oncology, Inc. in Q4 2018 and held it in 3 quarters.
  • Antara Capital's Clovis Oncology, Inc. position peaked at $2.15M in Q4 2018.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2019.

Based on Antara Capital's 13F filing for Q3 2019, filed 14 Nov 2019.